#Italy #Milan #Hansoh Pharma #Olatorepatide #EASD Meeting

Olatorepatide: A Revolutionary Dual GLP-1/GIP Agonist for Weight Management

The 2026 Annual Meeting of the European Association for the Study of Diabetes (EASD) held from September 28 to October 2 in Milan, Italy, showcased groundbreaking findings about Olatorepatide, a dual-acting agonist developed by Hansoh Pharma. This oral presentation highlighted data from the Phase III LIGHTEN study, which evaluated the efficacy and tolerability of Olatorepatide in adults struggling with overweight or obesity.

Study Overview

The LIGHTEN study was a multicenter, randomized, double-blind, placebo-controlled trial involving 604 adult participants in China. Eligible subjects had a Body Mass Index (BMI) of 28 kg/m² or higher, or a BMI of between 24 and 28 kg/m² alongside at least one weight-related comorbidity. Participants were assigned to receive weekly subcutaneous injections of Olatorepatide at doses of 5 mg, 10 mg, or 15 mg, or a placebo for 48 weeks.

Results Summary

The findings were striking. The group receiving the 15 mg dose of Olatorepatide demonstrated an average weight loss of 19.3% by week 48, without any observed plateau in weight reduction. Additionally, participants experienced an average reduction of 16.0 cm in waist circumference. The rates of gastrointestinal side effects, such as nausea (7.8%) and vomiting (4.9%), were notably low compared to existing treatments in this category.

When examining the primary endpoints of the study, which included percent change in body weight from baseline and the percentage of participants achieving a weight loss of 5% or more, results were overwhelmingly favorable. After 48 weeks, the observed weight loss percentages were 12.5%, 17.5%, and 19.3% for the 5 mg, 10 mg, and 15 mg Olatorepatide groups, respectively, compared to just -2.7% in the placebo group. A significant number of participants achieved key weight loss goals: 87.3% in the 5 mg group, 97.2% in the 10 mg group, and 95.2% in the 15 mg group lost at least 5% of their body weight.

Continuous Benefits

A noteworthy aspect of the data was the continuous downward trend in weight loss observed over the 48-week period, suggesting that prolonged treatment might yield even greater benefits. Moreover, participants also enjoyed improvements in metabolic parameters, including better blood pressure, lipid profile, hemoglobin A1c (HbA1c) levels, and significant reductions in insulin resistance measures (HOMA-IR).

Safety Profile

The safety profile for Olatorepatide was comparable to other approved therapies in the market for weight management. The incidences of adverse gastrointestinal events were significantly lower than those reported for currently available drugs in the same category, showcasing its potential as a safer alternative. Remarkably, no participants discontinued the treatment due to adverse events linked to Olatorepatide.

Conclusion

Olatorepatide, as a dual GLP-1/GIP receptor agonist, offers a novel mechanism for combating obesity with both efficacy in weight management and an impressive safety record. This Phase III study not only endorses Olatorepatide's role as a promising treatment option for adults battling excess weight but also emphasizes its multifaceted benefits on overall metabolic health. Given this evidence, the future for Olatorepatide in clinical practice appears bright.

The EASD Annual Meeting is recognized globally as a significant scientific conference focusing on diabetes and metabolic disorders. The selection of the Phase III data on Olatorepatide for presentation highlights the quality and clinical significance of these findings, reinforcing the compound's potential in the realm of weight management therapies.

Currently, Olatorepatide is under further clinical investigation in China for treating Type 2 diabetes, solidifying Hansoh Pharma's commitment to innovative solutions for complex health issues. This dedication, encapsulated in their mission of